secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001213900-26-023881
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance
--------------------------------------------------------------------------

- Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.
- FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.
- Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.
- Board approved $75M share repurchase program; cash and short-term investments $148.5M.
- Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/0001213900-26-023881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-023881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer